{"entity":{"id":"idea-fund-abbreviated-pathway-me-too-biologics","kind":"idea","name":"An abbreviated approval path for follow-on antibodies within a validated class","aka":[],"tldr":"Once a class of antibody such as PD-1 blockers is proven, later copies could be approved on smaller trials showing equivalence, forcing price competition and freeing patients and money for genuinely new drugs.","summary":"For mechanistic classes with multiple approved agents and well-understood pharmacology (anti-PD-1, anti-CD20, anti-HER2), regulators create a pathway between biosimilar approval and a full new-drug approval: approval based on pharmacodynamic equivalence and a single non-inferiority efficacy trial against an approved class member, with pricing expected to follow biosimilar dynamics. This ends the wasteful situation in which each of a dozen PD-1 antibodies runs its own placebo- or chemotherapy-controlled phase 3 in populations already known to benefit, while giving payers real competition within class. Capital that cannot earn novel-drug returns on copies moves elsewhere.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)","url":"https://doi.org/10.1038/d41573-022-00030-4"}],"tags":[],"related":["idea-fund-benefit-indexed-exclusivity","idea-fund-head-to-head-mandate"],"cancers":[],"sections":[],"technologies":[],"targets":["pd1","cd20","her2"],"drugs":["pembrolizumab","nivolumab","trastuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-drug-pricing","b-trial-design"],"keyPapers":["paper-upadhaya-nat-rev-drug-discov"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"An abbreviated class pathway reduces net prices of the affected class by at least 30% within three years of the first abbreviated approval and reduces the number of full-scale placebo-controlled phase 3 trials of later-in-class agents in the class.","rationale":"Biosimilar pathways cut prices for rituximab and trastuzumab substantially in Europe; several later PD-1 antibodies approved in China are already priced far below Western incumbents. The clinical pharmacology of these classes is well enough understood that repeating full development adds little knowledge.","test":"Regulator consultation and a pilot pathway for one class (anti-PD-1) with defined equivalence criteria, tracking approvals, trial designs and net prices over four years.","maturity":"speculative","actor":"regulator","cost":"small","horizonYears":4},"route":"/ideas/idea-fund-abbreviated-pathway-me-too-biologics/","neighbours":{"idea":[{"id":"idea-fund-head-to-head-mandate","kind":"idea","name":"Require head-to-head trials against the best in class for later entrants","route":"/ideas/idea-fund-head-to-head-mandate/"},{"id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"paper":[{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/"}]}}